1Bone Marrow and Stem Cell Transplant Program, Hematology-Oncology Division, Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, PA, USA.
Non-myeloablative allogeneic cell therapy (ACT) leverages the graft-versus-tumor (GVT) effect for hematologic diseases. This approach reduces conditioning toxicity, expanding eligibility for stem cell transplantation (SCT).
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: